Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 06 2022
27 06 2022
Historique:
received:
14
01
2022
accepted:
02
06
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
Recombinant human endostatin (Endostar) plus vinorelbine/cisplatin (NP) had been approved for the treatment of non-small cell lung cancers (NSCLC). But the real-world treatment pattern and effectiveness of Endostar plus other combination chemotherapy, namely docetaxel/platinum (DP), gemcitabine/platinum (GP), pemetrexed/platinum (PP), and paclitaxel/platinum (TP) in both treatment-naïve and re-treatment patients with advanced NSCLC were still unclear. A retrospective observational study was conducted based on the electronic medical record (EMR) system and advanced patients with NSCLC were identified from 7 cancer hospitals in China from 2012 to 2019. These patients were divided into five groups, Endostar plus NP, Endostar plus DP, Endostar plus GP, Endostar plus PP, and Endostar plus TP groups. The disease control rate (DCR), overall response rate (ORR), and the progression-free survival (PFS) were evaluated. Of the eligible 512 advanced patients with NSCLC, 10.35% were in Endostar plus NP group, while the numbers were 15.43%, 32.42%, 26.56%, 15.23% in Endostar plus DP group, Endostar plus GP group, Endostar plus PP group, and Endostar plus TP group, respectively. The ORRs were 31%, 28%, 22%, 41% and 27%, and the DCRs were 71%, 72%, 57%, 72% and 76%, respectively. The median of PFSs for the above groups were 7.9, 6.8, 5.6, 13.7, and 5.4 months. Compared with Endostar plus NP group, the hazard ratios (HRs) and 95%CIs of Endostar plus other chemotherapy were 1.86 (0.75-4.61), 2.15 (0.83-5.60), 1.33 (0.51-3.44), and 2.42 (0.86-6.81). This real-world study found the effectiveness of Endostar plus DP, Endostar plus GP, Endostar plus PP, and Endostar plus TP were of no statistically significant differences compared with Endostar plus NP and reflected the good effectiveness of Endostar plus different chemotherapy in advanced patients with NSCLC.
Identifiants
pubmed: 35761010
doi: 10.1038/s41598-022-14222-w
pii: 10.1038/s41598-022-14222-w
pmc: PMC9237081
doi:
Substances chimiques
Endostatins
0
Recombinant Proteins
0
Pemetrexed
04Q9AIZ7NO
Platinum
49DFR088MY
endostar protein
GVG18ZDN65
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
10841Informations de copyright
© 2022. The Author(s).
Références
Open Med (Wars). 2018 Apr 19;13:142-147
pubmed: 29696151
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biochem Biophys Res Commun. 2007 Sep 14;361(1):79-84
pubmed: 17644065
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Thorac Cancer. 2018 Nov;9(11):1354-1360
pubmed: 30152052
Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):283-90
pubmed: 21108883
Cancer Lett. 2009 Sep 8;282(1):9-13
pubmed: 19136200
J Clin Oncol. 2009 Jul 10;27(20):3277-83
pubmed: 19470938
Zhonghua Yi Xue Za Zhi. 2009 Apr 21;89(15):1057-9
pubmed: 19595257
Invest New Drugs. 2012 Jun;30(3):1144-9
pubmed: 21225314
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
J Thorac Oncol. 2011 Jun;6(6):1104-9
pubmed: 21532504
Sci Rep. 2018 Oct 26;8(1):15837
pubmed: 30367145
Thorac Cancer. 2018 May;9(5):606-612
pubmed: 29575575
Exp Cell Res. 2006 Mar 10;312(5):594-607
pubmed: 16376330